PROSTest - Wren Laboratories

Development and validation of a Multigenomic Liquid Biopsy (PROSTest) for Prostate Cancer Detection

A Response Biomarker for LU-PSMA Radionuclide Prostate Cancer Therapy (AC-Basel Abstract)

Evaluation of a novel transcriptomic tumor signature (PROSTest) as response biomarker for177Lu-PSMA therapy in advanced prostate cancer

PROSTest

New Molecular Liquid Biopsy Biomarker for Prostate Cancer

With the prostate-specific antigen (PSA) test now considered a less-than-reliable screen for prostate cancer, a worldwide search is under way to find an inexpensive, minimally invasive, and more effective tool to replace what was once considered the gold standard biomarker.

PROSTest

Barbados Prostrate Cancer Diagnostic Breakthrough

Barbadian doctors said Friday they are on the verge of groundbreaking research on a test for the illness which they believe could significantly reduce the prostate cancer epidemic and remove the often-daunting rectal examination to find the disease.

News PROSTest

Wren PROSTest utilized in Barbados Cancer Society Study

Yale University, Wren Laboratories and the Barbados Cancer Society have teamed to screen over 500 Barbadian men for molecular signatures indicating the presence of prostate cancer.

PROSTest

New Multi-Gene Liquid Biopsy Biomarker for Prostate Cancer

Relative to prostate-specific antigen (PSA), our mRNA-based diagnostic emerges as a more dependable biomarker, with an accuracy rate exceeding 90%, and readily repeatable while providing real-time information.

Diagnostics PROSTest